This six-month study comparing the effectiveness and safety of the widely prescribed hypertension drug Ramipril vs Takeda Pharmaceutical’s investigational TAK-491 is recruiting at 76 centers in the Netherlands, Sweden, Bulgaria, Finland, Germany, Poland, Ukraine, Estonia, Russia, Slovakia, Serbia.
Study title: “ Efficacy and Safety Study of TAK-491 Compared to Ramipril for Treating Essential Hypertension,” ID # NCT00760214.
To quote from the detailed description at ClinicalTrials.gov (http://www.clinicaltrials.gov/ct2/show/NCT00760214):
“Although antihypertensive agents are effective at the appropriate dose, the majority have side effects that limit their use. Angiotensin-converting enzyme inhibitors are commonly associated with cough and more rarely with angioedema. Beta-blockers are associated with fatigue and erectile dysfunction, calcium antagonists with peripheral edema and diuretics with metabolic complications.
“As a class, angiotensin II receptor blockers generally are considered more tolerable than other classes of hypertensive agents, although there is still a need for compounds with improved tolerability and efficacy for the treatment of hypertension. TAK-491 is an angiotensin II receptor blocker with high affinity for, and selective antagonistic activity at, the angiotensin II type 1 receptor, and is being developed for clinical use as an antihypertensive agent.”
“Ramipril is an angiotensin-converting enzyme inhibitor widely prescribed in Europe and Asia for the treatment of mild to moderate essential hypertension. This study is designed to compare the efficacy and safety/tolerability of TAK-491 and Ramipril for the treatment of hypertension.”
To Find More Information, Review Study Locations, and Contact the Study Managers: click here